#Coronavirus Disease Research #References (AMEDEO, August 29 '26)

 

Antiviral Res

1. PU F, Guo Y, Pan X, Liu X, et al
   Dual-targeting engineered binding proteins block SARS-CoV-2 infection and complement activation.
   Antiviral Res. 2026;254:106515.
   PubMed         Abstract available
   
   

   
   Clin Infect Dis

2. TRAUTNER BW, Cortes-Penfield NW, Gupta K, Hirsch EB, et al
   Clinical Practice Guideline by Infectious Diseases Society of America (IDSA): 2025 Guideline on Management and Treatment of Complicated Urinary Tract Infections: Selection of Antibiotic Therapy for Complicated UTI.
   Clin Infect Dis. 2025 Dec 19:ciaf460. doi: 10.1093.
   PubMed        
   
   
3. TRAUTNER BW, Cortes-Penfield NW, Gupta K, Hirsch EB, et al
   Clinical Practice Guideline by Infectious Diseases Society of America (IDSA): 2025 Guideline on Management and Treatment of Complicated Urinary Tract Infections: Timing of Intravenous to Oral Antibiotics Transition for Complicated UTI.
   Clin Infect Dis. 2025 Dec 19:ciaf461. doi: 10.1093.
   PubMed        
   
   

   
   Infect Control Hosp Epidemiol

4. PRAKASH-ASRANI R, Shioda K, Bower CW, Steinberg JP, et al
   Impact of hand hygiene on the detection of multidrug-resistant organisms and other pathogens of epidemiologic significance after implementation of an automated hand hygiene monitoring system.
   Infect Control Hosp Epidemiol. 2026 Aug 27:1-7. doi: 10.1017/ice.2026.10524.
   PubMed         Abstract available
   
   

   
   Int J Infect Dis

5. WAGATSUMA K, Song Z, Lam TTY, Kwok KO, et al
   Changes in respiratory virus seasonality across the COVID-19 pandemic: a multicentre comparative study in Leicester, Rotterdam, Hong Kong, and Christchurch.
   Int J Infect Dis. 2026 Aug 27:109080. doi: 10.1016/j.ijid.2026.109080.
   PubMed         Abstract available
   
   
6. RAGHUVAMSI PV, Loh SB, Bhattacharya P, Ho J, et al
   Investigating the effectiveness of multimodal data in forecasting SARS-COV-2 case surges.
   Int J Infect Dis. 2026 Aug 25:109062. doi: 10.1016/j.ijid.2026.109062.
   PubMed         Abstract available
   
   

   
   J Infect

7. SANDERSON ND, Dingle KE, Hopkins KMV, Vaughan A, et al
   Clinical validation of an optimised metagenomic nanopore sequencing method for detecting viral respiratory pathogens.
   J Infect. 2026 Aug 22:106839. doi: 10.1016/j.jinf.2026.106839.
   PubMed         Abstract available
   
   

   
   J Med Virol

8. LI J, Song W, Li J, Peng R, et al
   Enhanced Immunogenicity and Cross-Neutralizing Activity of a Trivalent Adenoviral Vector-Based SARS-CoV-2 Vaccine in Mice.
   J Med Virol. 2026;98:e71119.
   PubMed         Abstract available
   
   

   
   J Virol

9. LIU G, Chen J, Wu F, Wei P, et al
   Nanobodies targeting SARS-CoV-2 papain-like protease exert dual antiviral and anti-inflammatory effects.
   J Virol. 2026 Aug 28:e0059926. doi: 10.1128/jvi.00599.
   PubMed         Abstract available
   
   
10. STADLER E, Mordant F, Gartner M, Docken SS, et al
    Reconciliation of titer differences between SARS-CoV-2 neutralizing antibody assays.
    J Virol. 2026 Aug 27:e0082326. doi: 10.1128/jvi.00823.
    PubMed         Abstract available
    
    
11. DE BEIJER NL, Limpens RWAL, Barcena M, Snijder EJ, et al
    Conserved structural features of RNA export pores spanning the double membrane of arterivirus and coronavirus replication organelles.
    J Virol. 2026 Aug 26:e0085926. doi: 10.1128/jvi.00859.
    PubMed         Abstract available
    
    
12. KUMAR S, Lai L, Ellis ML, Patel A, et al
    Immunological imprinting shapes the cross-reactive antibody responses to the KP.2 and LP.8.1 vaccine doses.
    J Virol. 2026 Aug 26:e0074926. doi: 10.1128/jvi.00749.
    PubMed         Abstract available
    
    

    
    JAMA

13. CHUNG TH, Raj SR
    Postural Orthostatic Tachycardia Syndrome (POTS): A Review.
    JAMA. 2026 Aug 24. doi: 10.1001/jama.2026.14809.
    PubMed         Abstract available